Over the past several years, the federal government has consulted widely in formulating new rules for the regulation of brand-name drug prices through the Patented Medicine Prices Review Board (PMPRB) and a long-delayed set of rules that are expected to result in large price reductions, now...

With annual spending of about $4.5 billion dollars in 2010, Canada’s largest drug plan - the Ontario Drug Program (ODB) - will become harder to afford as the babyboomers age and workforce growth slows. A business-as-usual approach to funding the plan, which provides publicly funded drug...